Pharma Managers Series – HSE Briefing

We’re delighted to welcome HSE CEO, Paul Reid back to the PMI to give our members an update on where the HSE is versus plans, how they’re coping with the Covid pandemic and what the next 12 months holds. 

Please note this event is rescheduled from October 22nd to November 5th. 

Paul Reid, Chief Executive Officer – HSE 

Paul has led large organisations in the private, not for profit, central and local Government sectors. In May 2019 he was appointed as Chief Executive Officer of the Health Service Executive.  Paul has the privilege of leading over 117,000 dedicated staff who deliver a wide range of health services across Ireland.  Paul is a passionate public servant whose vision for the health service is to focus on long term planning by implementing Sláintecare and delivering effective and safe services within available resources. 

From 2014 to 2019 he was Chief Executive of Fingal County Council, one of the largest Local Authorities in the state.  Under his leadership, Fingal was the leading local authority in terms of social and private housing development.  It also led the way in terms of attracting Foreign Direct Investment and job creation across all sectors, through active land management and working with National State Agencies.   

Between 2011 and 2014, Paul worked as the Chief Operations Officer in the Department of Public Expenditure & Reform.  He was responsible for leading a whole set of reforms across the public service.  In this role he negotiated the Haddington Road Agreement, with the 26 Public Service Trade Unions, to reduce the public service pay bill by €1BN.

From 2010 to 2011, Paul worked as Head of Corporate Affairs with Trócaire, the Irish International Aid Agency.   Whilst there, he worked on an agenda to strengthen the overall governance of the organisation and on the implementation of best practice in HR, Finance, Risk Management and Communications.

Paul’s previous career was as the Executive Director of Networks & Operations with Eircom, the leading Irish telecommunications organisation.   He carried out a number of other roles within Eircom in Sales, Marketing and Contact Centre Management.    

Paul holds a Masters in Business Administration from Trinity College and a BA in Human Resources and Industrial Relations from the National College Ireland.

Paul is committed to building confidence and trust in our health service by supporting staff to deliver quality patient care through a new model of integrated services.

—-

Brenda Dooley, Founder & CEO – AXIS Consulting 

Brenda established AXIS 9 years ago to help pharmaceutical companies achieve success with their reimbursement applications for novel, innovative medicines in Ireland. With over 21 years’ experience in Irish Market Access and reimbursement applications, Brenda is an expert strategist, with a reputation for solving complex technical challenges and navigating challenging routes to market for Patients, Payers and Pharma.
Brenda holds a BA (Hons) in Business, a Diploma (Hons) in Financial Management and a MSc (Hons) in Health Economics from the National University of Ireland, Galway (NUI Galway).

Marian Hernon, Associate Director – AXIS Consulting

Marian leads the technical team to develop high quality and customised submissions for agencies such as the NCPE, SMC and BeNeLuxA. Marian has worked in the area of population health and health services research for over 7 years, conducting systematic reviews, developing micro-costing studies and completing cost-effectiveness analysis across the academic and pharmaceutical sectors.
Marian holds a BA (Hons) in Sociology and Political Science and an MA (Hons) in Population Health and Health Promotion from NUI Galway.

——–

As Irelands leading provider of Market Access and Reimbursement submission services, AXIS Consulting are delighted to sponsor the PMI event on Nov 5^th  AXIS will also contribute to the agenda highlighting their recent research findings on reimbursement timelines in Ireland and also outline some practical considerations to increase the speed at which new innovative medicines reach Irish patients.